Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mild cognitive impairment: the Manchester consensus.
Dunne RA, Aarsland D, O'Brien JT, Ballard C, Banerjee S, Fox NC, Isaacs JD, Underwood BR, Perry RJ, Chan D, Dening T, Thomas AJ, Schryer J, Jones AM, Evans AR, Alessi C, Coulthard EJ, Pickett J, Elton P, Jones RW, Mitchell S, Hooper N, Kalafatis C, Rasmussen JGC, Martin H, Schott JM, Burns A. Dunne RA, et al. Among authors: jones rw, jones am. Age Ageing. 2021 Jan 8;50(1):72-80. doi: 10.1093/ageing/afaa228. Age Ageing. 2021. PMID: 33197937 Free PMC article.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns A, O'Brien J; BAP Dementia Consensus group; Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Burns A, et al. J Psychopharmacol. 2006 Nov;20(6):732-55. doi: 10.1177/0269881106068299. J Psychopharmacol. 2006. PMID: 17060346 Review.
Donepezil for the treatment of agitation in Alzheimer's disease.
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Howard RJ, et al. Among authors: jones rw. N Engl J Med. 2007 Oct 4;357(14):1382-92. doi: 10.1056/NEJMoa066583. N Engl J Med. 2007. PMID: 17914039 Free article. Clinical Trial.
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team. Jones R, et al. Trials. 2009 Jul 24;10:57. doi: 10.1186/1745-6215-10-57. Trials. 2009. PMID: 19630974 Free PMC article. Clinical Trial.
Determining the minimum clinically important differences for outcomes in the DOMINO trial.
Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R. Howard R, et al. Int J Geriatr Psychiatry. 2011 Aug;26(8):812-7. doi: 10.1002/gps.2607. Epub 2010 Sep 16. Int J Geriatr Psychiatry. 2011. PMID: 20848576
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP. Howard R, et al. Lancet Neurol. 2015 Dec;14(12):1171-81. doi: 10.1016/S1474-4422(15)00258-6. Epub 2015 Oct 27. Lancet Neurol. 2015. PMID: 26515660 Clinical Trial.
812 results